Taiho Oncology, Inc.
Elizabeth Albino has a diverse work experience within the pharmaceutical industry. Elizabeth started their career as a Senior Product Specialist at J & J, Tibotec Therapeutics in 2005. From 2006 to 2007, they worked as a Professional Oncology Representative at Cytogen Corporation. In 2008, they became an Oncology Account Specialist at Cephalon, where they successfully launched Treanda and promoted Trisenox. Elizabeth then joined Bristol-Myers Squibb in 2011 as a Sr. Territory Business Manager. Finally, in 2015, they joined TAIHO ONCOLOGY INC as an Oncology Account Manager, where they played a crucial role in launching various cancer treatments.
Elizabeth Albino attended Rutgers University from 1983 to 1988, where they earned a Bachelor of Science degree in Engineering. From 1998 to 2000, they pursued their Master of International Affairs degree in International Finance and Business at Columbia University's School of International and Public Affairs (SIPA).
This person is not in the org chart
This person is not in any offices
Taiho Oncology, Inc.
2 followers
The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a world-class clinical development organization. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada. For more information, visit www.taihooncology.com